Late-onset neutropenia in patients with rheumatoid arthritis after treatment with rituximab

Journal of Rheumatology

Volumn 41, Issue 5, 2014, Pages 858-861

  Abdulkader, Rita ^a,b   Dharmapalaiah, Chethana ^b   Rose, Ginny ^c   Shand, Lynne M ^a   Clunie, Gavin P ^a   Watts, Richard A ^d  

^a IPSWICH HOSPITAL NHS TRUST   (United Kingdom)

^b NORFOLK AND NORWICH UNIVERSITY HOSPITAL   (United Kingdom)

^c BASILDON HOSPITAL   (United Kingdom)

^d CAMBRIDGE UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Adverse effects; Biological therapy; Neutrophils; Rheumatoid arthritis

Indexed keywords

ADALIMUMAB; ALEMTUZUMAB; AZATHIOPRINE; CYCLOSPORIN; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; GOLD; GRANULOCYTE COLONY STIMULATING FACTOR; HYDROXYCHLOROQUINE; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; RITUXIMAB; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; ANTIRHEUMATIC AGENT; MONOCLONAL ANTIBODY;

ADULT; AGED; ARTICLE; B LYMPHOCYTE; BLOOD CELL COUNT; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE DURATION; FEMALE; HUMAN; INCIDENCE; LATE ONSET NEUTROPENIA; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; PNEUMONIA; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RHEUMATOID ARTHRITIS; VERY ELDERLY; ARTHRITIS, RHEUMATOID; CHEMICALLY INDUCED; COMPLICATION; MIDDLE AGED; OPPORTUNISTIC INFECTION; REMISSION; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BLOOD CELL COUNT; FEMALE; HUMANS; MALE; MIDDLE AGED; NEUTROPENIA; OPPORTUNISTIC INFECTIONS; REMISSION, SPONTANEOUS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84899768854     PISSN: 0315162X     EISSN: 14992752     Source Type: Journal    
DOI: 10.3899/jrheum.130526     Document Type: Article

References (9)

1. Tesfa D, Ajeganova S, Hägglund H, Sander B, Fadeel B, Hafström I, et al. Late-onset neutropenia following rituximab therapy in rheumatic diseases: association with B lymphocyte depletion and infections. Arthritis Rheum 2011;63:2209-14.
2. Wolach O, Bairey O, Lahav M. Late-onset neutropenia after rituximab treatment: case series and comprehensive review of the literature. Medicine 2010;89:308-18.
3. Fukuno K, Tsurumi H, Ando N, Kanemura N, Goto H, Tanabashi S, et al. Late-onset neutropenia in patients treated with rituximab for non-Hodgkin's lymphoma. Int J Hematol 2006;84:242-7. (Pubitemid 44619246)
4. Voog E, Morschhauser F, Solal-Céligny P. Neutropenia in patientstreated with rituximab. N Engl J Med 2003;348:2691-4.
5. Tesfa D, Gelius T, Sander B, Kimby E, Fadeel B, Palmblad J, et al. Late-onset neutropenia associated with rituximab therapy: evidence for a maturation arrest at the (pro)myelocyte stage of granulopoiesis. Med Oncol 2008;25:374-9.
6. Weng WK, Negrin RS, Lavori P, Horning SJ. Immunoglobulin G Fc receptor FcgammaRIIIa 158 V/F polymorphism correlates with rituximab-induced neutropenia after autologous transplantation in patients with non-Hodgkin's lymphoma. J Clin Oncol 2010;28:279-84.
7. Li SC, Chen YC, Evens AM, Lee CC, Liao HF, Yu CC, et al. Rituximab-induced late-onset neutropenia in newly diagnosed B-cell lymphoma correlates with Fc receptor FcγRIIIa 158(V/F) polymorphism. Am J Hematol 2010;85:810-2.
8. Dunleavy K, Hakim F, Kim HK, Janik JE, Grant N, Nakayama T, etal. B-cell recovery following rituximab-based therapy is associated with perturbations in stromal derived factor-1 and granulocyte homeostasis. Blood 2005;106:795-802.
9. Besada E. Alternative explanations for development of late-onset neutropenia in rituximab-treated rheumatic disease patients: comment on the article by Tesfa et al [letter]. Arthritis Rheum2012;64:596-7.